The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
Thomas H. Cartwright
Employment or Leadership Position - McKesson Specialty Health
Consultant or Advisory Role - Celgene
Aimee Ginsburg
Employment or Leadership Position - McKesson
Stock Ownership - Celgene (B)
Lalan S. Wilfong
Employment or Leadership Position - McKesson Specialty Health
Robyn K. Harrell
Employment or Leadership Position - McKesson Specialty Health
J. Russell Hoverman
Employment or Leadership Position - McKesson Specialty Health